文献速递淋巴瘤

BCL-W 对部分伯基特淋巴瘤和弥漫大 B 细胞淋巴瘤细胞系的持续生存并非必需

BCL-W is dispensable for the sustained survival of select Burkitt lymphoma and diffuse large B-cell lymphoma cell lines.
PubMed 文献 · Blood Adv · 2020-01-01

本研究探讨 BCL-W 在伯基特淋巴瘤(BL)和弥漫大 B 细胞淋巴瘤(DLBCL)细胞系持续生长中的作用。通过 CRISPR/Cas9 敲除或 shRNA 敲低 BCL-W,未诱导自发凋亡,也未改变对靶向其他 BCL-2 促生存蛋白的 BH3 模拟物的敏感性。提示 BCL-W 并非普遍维持 BL 和 DLBCL 细胞系生长存活所必需,靶向 BCL-W 在该亚组 B 细胞淋巴瘤中可能无广泛治疗获益。

要点

  • CRISPR/Cas9 敲除或 shRNA 敲低 BCL-W 未导致 BL 和 DLBCL 细胞系自发凋亡。
  • BCL-W 缺失不影响细胞对靶向其他 BCL-2 促生存蛋白的 BH3 模拟物的敏感性。
  • BCL-W 并非普遍维持 BL 和 DLBCL 细胞系生长存活所必需。

核心结论

  • BCL-W 并非普遍维持人 BL 和 DLBCL 细胞系持续生长和存活所必需,靶向 BCL-W 在该亚组 B 细胞淋巴瘤中可能无广泛治疗获益。

研究设计与样本

  • 采用 CRISPR/Cas9 介导的 BCL-W 缺失或短发夹 RNA(shRNA)介导的 BCL-W 敲低,在选定的 BL 和 DLBCL 细胞系中研究 BCL-W 对持续生长的作用。

主要发现

  • 在选定的 BL 和 DLBCL 细胞系中,CRISPR/CAS9 介导的 BCL-W 缺失或 shRNA 介导的 BCL-W 敲低未导致自发凋亡。
  • BCL-W 缺失或敲低对一系列靶向其他 BCL-2 促生存蛋白的 BH3 模拟物的敏感性无影响。

临床怎么用

  • 提示在 BL 和 DLBCL 中靶向 BCL-W 可能不是广泛有效的治疗策略,需进一步评估 BCL-W 作为治疗靶点的适用人群。

局限性

  • 研究仅基于选定的 BL 和 DLBCL 细胞系,结果不能直接推广至患者样本或其他 B 细胞淋巴瘤亚型。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Dysregulated expression of BCL-2 family proteins allows cancer cells to escape apoptosis. To counter this, BH3-mimetic drugs that target and inhibit select BCL-2 prosurvival proteins to induce apoptosis have been developed for cancer therapy. Venetoclax, which targets BCL-2, has been effective as therapy for patients with chronic lymphocytic leukemia, and MCL-1-targeting BH3-mimetic drugs have been extensively evaluated in preclinical studies for a range of blood cancers. Recently, BCL-W, a relatively understudied prosurvival member of the BCL-2 protein family, has been reported to be abnormally upregulated in Burkitt lymphoma (BL), diffuse large B-cell lymphoma (DLBCL), and Hodgkin lymphoma patient samples. Therefore, to determine if BCL-W would be a promising therapeutic target for B-cell lymphomas, we have examined the role of BCL-W in the sustained growth of human BL- and DLBCL-derived cell lines. We found that CRISPR/CAS9-mediated loss or short hairpin RNA-mediated knockdown of BCL-W expression in selected BL and DLBCL cell lines did not lead to spontaneous apoptosis and had no effect on their sensitivity to a range of BH3-mimetic drugs targeting other BCL-2 prosurvival proteins. Our results suggest that BCL-W is not universally required for the sustained growth and survival of human BL and DLBCL cell lines. Thus, targeting BCL-W in this subset of B-cell lymphomas may not be of broad therapeutic benefit.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Diepstraten ST, Chang C, Tai L, et al. BCL-W is dispensable for the sustained survival of select Burkitt lymphoma and diffuse large B-cell lymphoma cell lines. Blood Adv. 2020. PMID: 31985804. doi:10.1182/bloodadvances.2019000541

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。